- Previous Close
4.0700 - Open
4.0500 - Bid 4.0900 x 100
- Ask 4.1600 x 200
- Day's Range
3.9875 - 4.1350 - 52 Week Range
3.0000 - 25.4500 - Volume
1,321,904 - Avg. Volume
1,108,783 - Market Cap (intraday)
189.736M - Beta (5Y Monthly) --
- PE Ratio (TTM)
-- - EPS (TTM)
-3.7200 - Earnings Date May 12, 2025 - May 17, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
11.18
CARGO Therapeutics, Inc., a clinical-stage biotechnology company, develops chimeric antigen receptor (CAR) T-cell therapies for cancer patients. The company's lead program is CRG-022, an autologous CD22 CAR T-cell product candidate designed to address resistance mechanisms by targeting CD22, an alternate tumor antigen that is expressed in B-cell malignancies. It also develops CRG-023, a tri-specific CAR T product candidate that targets tumor cells with three B-cell antigen targets. The company was formerly known as Syncopation Life Sciences, Inc. and changed its name to CARGO Therapeutics, Inc. in September 2022. CARGO Therapeutics, Inc. was incorporated in 2019 and is based in San Mateo, California.
cargo-tx.comRecent News: CRGX
View MorePerformance Overview: CRGX
Trailing total returns as of 4/1/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: CRGX
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: CRGX
View MoreValuation Measures
Market Cap
187.89M
Enterprise Value
-122.38M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
0.52
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-27.01%
Return on Equity (ttm)
-43.76%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-167.5M
Diluted EPS (ttm)
-3.7200
Balance Sheet and Cash Flow
Total Cash (mrq)
339.7M
Total Debt/Equity (mrq)
8.17%
Levered Free Cash Flow (ttm)
-93.51M